N⁶-Methoxy-2-aminoadenosin | 55652-73-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: N⁶-Methoxy-2-aminoadenosin
• 英文别名: 2-Amino-N⁶-methoxy-adenosin；1-(2-amino-6-methoxyamino-purin-9-yl)-β-D-1-deoxy-ribofuranose；2-amino-N6-methoxyadenosine；(2R,3R,4S,5R)-2-[2-amino-6-(methoxyamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 55652-73-8
• 化学式: C₁₁H₁₆N₆O₅
• 分子量: 312.285
• InChiKey: OQGMXBRSTMPDTL-KQYNXXCUSA-N

物化性质

• 沸点：
  723.3±70.0 °C(Predicted)
• 密度：
  2.02±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  161
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  6-氯鸟嘌呤核苷 、 3-氯苯甲酰乙腈 以 乙醇 、 水 为溶剂， 以63%的产率得到N⁶-Methoxy-2-aminoadenosin
  参考文献：
  名称：

  Anti-malarial activity of N6-modified purine analogues

  摘要：

  Plasmodium falciparum causes one of the deadliest forms of malaria and resistance to the currently available drugs makes it imperative to develop new, safe and potent drugs. Parasites such as P. falciparum are unable to synthesise purines de novo and to this end often have multiple purine uptake and salvage systems. With this in mind, we have designed and synthesised libraries of purine analogues as potential anti-malarial agents. Herein, we report three compounds with promising activity against the highly chloroquine-resistant VS1 P. falciparum namely: N-6-hydroxyadenine (1c), 2-amino-N-6-aminoadenosine (2b) and 2-amino-N-6-amino-N-6-methyladenosine (4b). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.05.038

文献信息

• Guide RNA with chemical modifications
  申请人：Agilent Technologies, Inc.

  公开号：US10337001B2

  公开（公告）日：2019-07-02

  The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.

  本发明涉及修饰的向导 RNA 及其在成簇、规则间隔、短回文重复序列（CRISPR）/CRISPR 相关（Cas）系统中的应用。
• Inhibition of viruses
  申请人：Medical Research Council

  公开号：US20030130226A1

  公开（公告）日：2003-07-10

  Disclosed is a pharmaceutical composition comprising a ribonucleoside analogue in accordance with general formula I or II as herein defined, in admixture with a physiologically acceptable excipient diluent or carrier.

  本发明公开了一种药物组合物，该组合物包含符合本文定义的通式 I 或 II 的核糖核苷类似物，并与生理上可接受的赋形剂稀释剂或载体混合。
• NOVEL ADENOSINE DERIVATIVES
  申请人：NOVO NORDISK A/S

  公开号：EP0607367A1

  公开（公告）日：1994-07-27
• IMPROVEMENTS IN OR RELATING TO INHIBITION OF VIRUSES
  申请人：Medical Research Council

  公开号：EP1441744A2

  公开（公告）日：2004-08-04
• GUIDE RNA WITH CHEMICAL MODIFICATIONS
  申请人：Agilent Technologies, Inc.

  公开号：EP3227447A1

  公开（公告）日：2017-10-11